The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide ...

The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European ...

CEOs from European drugmakers Sanofi and Novartis have inked a letter in The Financial Times urging the European Union to set ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, ...

In a report released today, James Quigley from Goldman Sachs maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price target ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €115.00. The ...

However investors are once again less than impressed by Sanofi’s M&A strategy - and whether the price will be 'a steal' will depend on Ablynx's long-term pipeline productivity. Sanofi's share ...

News on this is expected this week, and tariffs of 20% or more may be imposed, which is going to be bad news for the valuations and share prices of these companies. Making things worse for Sanofi ...

Sanofi last year recorded around 13 billion ... according to a document reviewed by Reuters. category Oil prices climb on short-covering, but tariff concerns linger 4:39 AM UTC · Updated ago ...

Novartis CEO Vas Narasimhan and Sanofi leader Paul Hudson wrote in Britain's Financial Times that European price controls and austerity measures reduce the attractiveness of its markets.